View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
January 17, 2020

New Wuhan coronavirus spreads to Thailand and Japan

By GlobalData Healthcare

On December 31 2019, China alerted the World Health Organization (WHO) about a mysterious outbreak of pneumonia in Wuhan, the capital of the Hubei province in Central-Eastern China. Wuhan is one of the most populous cities in China, with more than seven million inhabitants. Many of the 41 people who have been hospitalized due to this outbreak were workers or visitors of a live seafood and exotic animal market that has since shut down. As of January 17, two people have died from the infection.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Genetic sequencing quickly revealed that the pathogen responsible for the outbreak is a previously undetected coronavirus, the same family responsible for the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory (SARS) outbreaks. These viruses originate in bats and can be transmitted between animals and humans. During the 2003 SARS outbreak, thousands of people were infected and hundreds were killed while the virus spread to 37 countries. Chinese authorities have been trying to contain the spread of the new virus and have shared its genetic sequence to enable other countries to quickly identify new cases and respond accordingly. On January 13, the first case outside of China occurred in Thailand, where a tourist travelling from Wuhan was hospitalized with pneumonia. As of January 17, a new case of the virus was reported in Japan. However, to date, neither person-to-person spread of the virus nor cases among healthcare workers have been detected.

No specific treatment options or vaccines are available for coronavirus infections. Prevention is usually limited to an attempt to reduce the risk of infection by frequent hand washing; avoiding touching one’s eyes, nose, or mouth with unwashed hands; and avoiding contact with sick people. According to GlobalData’s proprietary drug database, three MERS vaccine candidates are in early-stage clinical trials. Inovio Pharmaceuticals’ DNA vaccine INO-4301 completed Phase I in 2019 and is recruiting for Phase I/II. Phase I studies include a recombinantly modified vaccinia virus Ankara (MVA) viral vector with

MERS glycoproteins from the Ludwig-Maximilians-University Munich, as well as Vaccitech’s VTP-500, which uses the proprietary chimpanzee adenovirus vector ChAdOx1 to deliver the coronaviral spike proteins. Several antiviral candidates targeting the viral surface spike proteins with the aim of prohibiting viral entry into host cells are in Phase I, including Regeneron’s REGN-3048 and REGN-3051, as well as SAB Biotherapeutics’ SAB-301. Furthermore, Gilead’s RNA polymerase inhibitor remdesivir is being tested for multiple viral indications such as SARS, MERS, Ebola, and Zika.

Rapid identification of pathogens and information sharing are imperative to allow global surveillance to contain the spread of the disease, especially during the ongoing cold and influenza season, as coronavirus infections initially show similar symptoms to respiratory-related hospitalizations due to cold and influenza. However, uncertainty about the transmission of the new Wuhan coronavirus poses a challenge and makes global alertness necessary even though vaccines and treatment options for coronavirus infections are in early clinical development.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology